The advanced glycation end products (AGEs) market comprises pharmaceutical products used to treat diseases caused due to accumulation of AGEs in the body. AGEs are a complex and heterogeneous group of compounds formed through non-enzymatic glycation and oxidation of proteins, lipids, and nucleic acids. Some key products in the market are aspirin, diltiazem, Benicar, Cozaar, and Diovan. The global AGEs market is an important therapeutic area as accumulation of these compounds in tissues and blood vessels is associated with conditions like diabetes, atherosclerosis, chronic kidney disease, neurological disorders, and even aging. The need for AGEs inhibiting therapeutics is expected to rise with the growing prevalence of the above-mentioned diseases worldwide.
The Global advanced glycation end products Market is estimated to be valued at US$3,469.95 Mn in 2024 and is expected to exhibit a CAGR of 12. % over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the advanced glycation end products (AGEs) market are Astellas Pharma, Calico, Geron Corporation, Human Biosciences, National Cancer Institute, Sanofi, Pfizer Inc. Key players are focusing on research and development activities to develop more effective therapies. In June 2019, a team of engineers from the MIT announced that they are developing a method of converting liquid nanoemulsions into solid gels.
The global AGEs market is witnessing high demand mainly due to the rising prevalence of diabetes and subsequent diabetic complications. It is estimated that over 537 million adults were living with diabetes in 2021 worldwide. As diabetes leads to elevated blood sugar levels and increase risk of developing CVDs and renal diseases over the long run, the need for AGEs management is growing.
With continuous technological advancements, new drugs and drug delivery systems are being developed to inhibit AGEs formation and break existing links between AGEs and tissues. Nanotechnologies have opened up possibilities of developing targeted drug delivery systems with minimal side effects. Researchers are working on nanoparticle-based therapeutics that can selectively migrate to areas of the body with high AGE accumulation like retina in case of diabetic retinopathy.
Market Trends
Some key trends being observed in the global advanced glycation end products market include:
- Focus on developing alternatives to existing drugs: With many drugs going off-patent, companies are putting increased efforts in discovering new chemical entities that can effectively inhibits AGEs formation as well as break existing links.
- Investments in preventive therapies: With lifestyle diseases rising, there is higher focus on developing preventive treatments through diet modification and AGEs restriction. Supplements and food products inhibiting non-enzymatic glycation are gaining prominence.
- Combination therapies gaining traction: Using complementary mechanisms, researchers are exploring efficacy of combining existing drugs rather than developing new single-molecule therapies.
Market Opportunities
The future growth opportunities in the global advanced glycation end products market lie in:
- Developing cost-effective AGEs diagnostics tests: Early detection is crucial but existing tests are often inaccessible in developing regions. Developing affordable point-of-care diagnostics can boost early treatment.
- Leveraging technological advancements: Technologies like nanomedicine, gene therapy are opening up avenues to develop targeted, precise and long-lasting AGEs modulating therapies.
Impact of COVID-19 on Advanced Glycation End Products Market Growth
The COVID-19 pandemic has significantly impacted the growth of the Advanced Glycation End Products market globally. Due to nationwide lockdowns imposed across various countries to curb the spread of the virus, there was a temporary halt in research and development activities, as well as production facilities. This led to disruptions in the supply chain and created a shortage of raw materials. Furthermore, with healthcare systems focused on the treatment of infected patients, resources allocated to chronic disease management reduced significantly during this period. However, with lockdowns now easing and facilities resuming operations with certain safety guidelines and protocols in place, the market is expected to bounce back steadily over the coming years. Advanced Glycation End Products manufacturers will need to focus on innovations to develop cost-effective and efficient treatment options. They must also strengthen supply chains through strategic partnerships and collaborations. Telehealth and digital health solutions can help bridge care gaps during another potential outbreak.
Geographical Regions with Highest Market Concentration
Currently, North America contributes the largest share to the global Advanced Glycation End Products market in terms of value, given the region's high prevalence of diabetes and related complications. The expanding diabetic population, along with availability of advanced healthcare infrastructure and growing awareness are major factors driving market growth. Europe follows North America as the second largest regional market. However, over the forecast period, Asia Pacific is identified as the fastest growing regional market on account of improving access to healthcare, rising healthcare spending, and increasing focus of key players on tapping growth opportunities in emerging countries of China, India, and Southeast Asia.
Fastest Growing Region - Asia Pacific
The Asia Pacific region is projected to witness the fastest growth in the Advanced Glycation End Products market during the forecast period. This is attributed to factors such as rising geriatric population, growing prevalence of chronic diseases including diabetes, increasing healthcare expenditures, expanding network of healthcare facilities, and improving access to modern treatment options in major Asian countries. Moreover, the presence of several developing economies provides ample opportunities for market players to invest in research and development as well as capacity expansion projects. Heightened patient awareness regarding the management of diabetic complications is another key factor fueling the demand for diagnostic tests and treatment therapies within Asia Pacific. Existing players are likely to focus their expansion strategies on emerging Asian markets to benefit from high growth rates in the long run.
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/
